Management of patients with familial hypercholesterolaemia (Q38528246)

3 September 2017

1 reference

title

Management of patients with familial hypercholesterolaemia (English)

1 reference

3 September 2017

0 references

1

Željko Reiner

1 reference

PubMed ID

26076948

3 September 2017

language of work or name

English

0 references

publication date

16 June 2015

1 reference

Nature Reviews Cardiology

3 September 2017

1 reference

3 September 2017

12

1 reference

3 September 2017

10

1 reference

3 September 2017

565-575

1 reference

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

3 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

A receptor-mediated pathway for cholesterol homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia: insight from the kinetic study using stable isotope and animal studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Advanced method for the identification of patients with inherited hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Mutation detection in Croatian patients with familial hypercholesterolemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Sudden Death in a 4-Year-Old Boy: A Near-Complete Occlusion of the Coronary Artery Caused by an Aggressive Low-Density Lipoprotein Receptor Mutation (W556R) in Homozygous Familial Hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

A comparison of European and US guidelines for familial hypercholesterolaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Statins in the primary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Homozygous familial hypercholesterolemia and its management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Adverse effects of statins - myths and reality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Predicting non-adherence in patients with familial hypercholesterolemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Prevalence and types of persistent dyslipidemia in patients treated with statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Resistance and intolerance to statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Combined therapy in the treatment of dyslipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Simvastatin with or without ezetimibe in familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Serious drug-induced liver disease secondary to ezetimibe.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Recommendations for the use of LDL apheresis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Role of lipid apheresis in changing times

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Lipoprotein apheresis: state of the art and novelties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Lomitapide for homozygous familial hypercholesterolaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Heart-liver transplantation in a patient with familial hypercholesterolaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: a pilot study

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.92

31 March 2020

12 December 2020

HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures

1 reference

12 December 2020

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

1 reference

12 December 2020

[Three-year-old boy--a homozygote for familiar hypercholesterolemia]

1 reference

12 December 2020

Preemptive liver transplantation in a child with familial hypercholesterolemia

1 reference

12 December 2020

The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2015.92

1 reference

3 September 2017

1 reference

PubMed ID

26076948